Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...
Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...
Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike ...
An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005). This is an ASCO ...
Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially within oncology by using multi-omics ...
The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...
On the one hand, circadian rhythm disorder contributes to tumor growth and metastasis by influencing the dysregulation of gene expression affecting the tumor itself. On the other hand, circadian ...
Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...
The emerging field of Cancer Neuroscience has revealed that the nervous system plays a pivotal role in cancer initiation, progression, and metastasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results